# Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)

Study · id `cardio:ct-nct01841697` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01841697](<https://clinicaltrials.gov/study/NCT01841697>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01841697

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 642 participants.

## Technical summary

Registry record NCT01841697. Randomized; double masking; primary purpose treatment. Start 2013-06-13 (actual); primary completion 2014-11-17 (actual). Results posted on 2015-11-25.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 642 participants (enrolled count; ClinicalTrials.gov record NCT01841697, source copy `cardio:ctgov-nct01841697-2018-09-10`, retrieved 2026-10-26)
- Started: 2013-06-13 (actual) (ClinicalTrials.gov record NCT01841697, source copy `cardio:ctgov-nct01841697-2018-09-10`, retrieved 2026-10-26)
- Primary completion: 2014-11-17 (actual) (ClinicalTrials.gov record NCT01841697, source copy `cardio:ctgov-nct01841697-2018-09-10`, retrieved 2026-10-26)
- Completion: 2014-11-17 (actual) (ClinicalTrials.gov record NCT01841697, source copy `cardio:ctgov-nct01841697-2018-09-10`, retrieved 2026-10-26)
- Results first posted: 2015-11-25 (ClinicalTrials.gov record NCT01841697, source copy `cardio:ctgov-nct01841697-2018-09-10`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01841697-2018-09-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
- Condition: Type 2 Diabetes
- Intervention (Drug): Omarigliptin
- Intervention (Drug): Sitagliptin
- Intervention (Drug): Placebo to omarigliptin
- Intervention (Drug): Placebo to Sitagliptin
- Intervention (Drug): Open-label Metformin
- Intervention (Drug): Open-label Glimepiride
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

## Provenance

Content hash: 30cdbbfc27b19c257aa783754f54b82c2388f253ca7d8d7da99da655cf2b405f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
